Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR3-Specific CTLs for Relapsed Myeloid Leukemias Post-Transplant
NCT00052598Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2002
- Primary completion
- Nov 2009
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PR1-specific T lymphocytes in acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Toxicity rate associated with infusing donor CD8+CTL clones specific for PR3. Started Sep 2002; status: terminated.
02
Drugs
PR1-specific T lymphocytes
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00052598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052598.